Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Barriuso

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Microbial Cell Factories|October 8, 2016
Enzymatic fine-tuning for 2-(6-hydroxynaphthyl) β-D-xylopyranoside synthesis catalyzed by the recombinant β-xylosidase BxTW1 from Talaromyces amestolkiaeManuel Nieto-Domínguez, Alicia Prieto, Beatriz Fernández de Toro, et al.
Cancer Letters|June 20, 2014
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyondCarlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, et al.
Plos One|October 19, 2018
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancersAngela Lamarca, Salvatore Galdy, Jorge Barriuso, et al.
Cancer Treatment Reviews|October 8, 2018
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumoursJorge Barriuso, Ana Custodio, Ruth Afonso, et al.
Neuroendocrinology|February 1, 2019
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine CarcinomasMelissa Frizziero, Francesca Spada, Angela Lamarca, et al.
BMJ Open|May 14, 2021
Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocolLindsay E Carnie, Angela Lamarca, Kate Vaughan, et al.
The Oncologist|May 26, 2018
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR StudyJaume Capdevila, Alexandre Teulé, Jorge Barriuso, et al.
Oncotarget|March 31, 2018
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumoursAngela Lamarca, Daisuke Nonaka, Wolfgang Breitwieser, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 20, 2026
Peritoneal metastasis histological grade independently predicts outcome in pseudomyxoma peritonei treated with curative surgeryAwen Hasan, Bipasha Chakrabarty, Christopher Kearsey, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Microbial Cell Factories|October 8, 2016
Enzymatic fine-tuning for 2-(6-hydroxynaphthyl) β-D-xylopyranoside synthesis catalyzed by the recombinant β-xylosidase BxTW1 from Talaromyces amestolkiaeManuel Nieto-Domínguez, Alicia Prieto, Beatriz Fernández de Toro, et al.
Cancer Letters|June 20, 2014
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyondCarlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, et al.
Plos One|October 19, 2018
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancersAngela Lamarca, Salvatore Galdy, Jorge Barriuso, et al.
Cancer Treatment Reviews|October 8, 2018
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumoursJorge Barriuso, Ana Custodio, Ruth Afonso, et al.
Neuroendocrinology|February 1, 2019
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine CarcinomasMelissa Frizziero, Francesca Spada, Angela Lamarca, et al.
BMJ Open|May 14, 2021
Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocolLindsay E Carnie, Angela Lamarca, Kate Vaughan, et al.
The Oncologist|May 26, 2018
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR StudyJaume Capdevila, Alexandre Teulé, Jorge Barriuso, et al.
Oncotarget|March 31, 2018
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumoursAngela Lamarca, Daisuke Nonaka, Wolfgang Breitwieser, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 20, 2026
Peritoneal metastasis histological grade independently predicts outcome in pseudomyxoma peritonei treated with curative surgeryAwen Hasan, Bipasha Chakrabarty, Christopher Kearsey, et al.
Pageof 14